Evolus Inc Profile

Performance

   

Odds of Distress

Check how we calculate scores
Equity ratings for Evolus Inc Common Stock are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting August 13, 2019 and ending today November 11, 2019. Click here to learn more.
Fiscal Quarter End: December 31, 2019   Follow

Evolus Inc Profile

Next fiscal quarter end is expected on December 31, 2019. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus Inc operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 228 people. more
Evolus Inc Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Evolus Common Stock SEC Filings
Evolus Inc SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameEvolus Inc Common Stock
President CEO, DirectorMurthy SimhambhatlaView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Drug Manufacturers - Specialty & Generic
InstrumentUSA Stock View All
LocationCalifornia; U.S.A
Business Address520 Newport Center Drive
ExchangeBATS Exchange
CUSIP30052C107
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
BenchmarkDOW
Websitewww.evolus.com
Phone949 284 4555
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestOctober 15, 2019
Evolus Inc Common Stock (EOLS) is traded on BATS Exchange in USA. It is located in 520 Newport Center Drive and employs 228 people. Evolus Inc is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 399.86 M. Evolus Common Stock conducts business under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 27.43 M outstanding shares of which 3.9 M shares are currently shorted by private and institutional investors with about 11.74 trading days to cover. The company currently holds about 74.03 M in cash with (89.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.7.
Check Evolus Inc Probability Of Bankruptcy

Ownership Allocation (%)

Evolus Inc Target Price Odds Analysis

Odds Below 14.58HorizonTargetOdds Above 14.58
91.02%30 days 14.58 8.96%
Based on normal probability distribution, the odds of Evolus Inc to move above current price in 30 days from now is about 8.96 (This Evolus Inc Common Stock probability density function shows the probability of Evolus Inc Stock to fall within a particular range of prices over 30 days) .

Evolus Common Stock Top Holders

Evolus Inc Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares1.3 M20.5 M
Wafra IncCommon Shares203.3 K3.2 M
Bank Of MontrealPut Options59.3 K926 K
Simplex Trading LlcCall Options253395 K
View Evolus Inc Diagnostics

Evolus Inc Common Stock Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Evolus Inc Key Fundamentals

Evolus Inc Against Markets

Did you try this?

Run Headlines Timeline Now

   

Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Evolus Inc Upcoming and Recent Events

Evolus Inc Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportMarch 16, 2020
Next Earnings ReportMay 5, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndMarch 16, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Evolus Inc Corporate Filings

Evolus Inc SEC Reporting

Financial Statements and Exhibits. Results of Operations and Financial Condition
Submission of Matters to a Vote of Security Holders
Unclassified Corporate Event

Evolus Inc Corporate Directors

Karah Parschauer Director
Robert Hayman Independent Director
Bosun Hau Independent Director
Additionally see Investing Opportunities. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.
Search macroaxis.com